AbbVie's Acquisition Strategy: A Catalyst for Growth in a Post-Humira Era

AbbVie has emerged as a standout performer in the healthcare sector, with its stock climbing 6% this year despite the broader S&P 500 healthcare index declining 1%. The pharmaceutical giant's ambitious transformation strategy involves navigating the post-Humira era through acquisitions and diversification. AbbVie has completed a series of acquisitions totaling over $22 billion in deal value, targeting high-growth therapeutic areas and reducing dependence on any single asset. The company's track record suggests its acquisition strategy can deliver exceptional returns, with its 2016 partnership with Boehringer Ingelberg resulting in $11.7 billion in sales for Skyrizi in 2024.